Urothelial Cancer

Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer

Lisa A. Raedler, PhD, RPh

2018 Third Annual Oncology Guide to New FDA Approvals - FDA Approvals, News & Updates, Urothelial Cancer

Urothelial carcinoma is the primary subtype of bladder cancer, which is the sixth most common cancer in the United States. More than 79,000 cases of bladder cancer were estimated to be diagnosed, and nearly 17,000 people to die from this disease in 2017. [ Read More ]

Adjuvant Chemotherapy in Upper-Tract Urothelial Cancer Shows Impressive Gains in the POUT Trial

Phoebe Starr

April 2018, Vol 8, No 4 - GU Cancers Symposium Highlights, Urothelial Cancer

Adjuvant chemotherapy had impressive gains in disease-free survival (DFS) and metastasis-free survival versus surveillance in upper-tract urothelial cancer (UTUC), according to the results of the phase 3 POUT clinical trial that were presented at the 2018 Genitourinary Cancers Symposium. There was a suggestion of a survival gain with chemotherapy, but longer follow-up is needed. [ Read More ]

Ramucirumab plus Docetaxel Superior to Docetaxel Monotherapy in Platinum-Refractory Advanced Urothelial Cancer

Phoebe Starr

December 2017, Vol 7, No 12 - ESMO Highlights, Urothelial Cancer

Ramucirumab (Cyramza), a vascular endothelial growth factor receptor 2 inhibitor, added to docetaxel improved progression-free survival (PFS) and nearly doubled the objective response rate (ORR) compared with docetaxel monotherapy in patients with advanced or metastatic urothelial cancer that progressed with platinum-based chemotherapy in the phase 3 RANGE clinical trial. This is the first phase 3 clinical trial to show a PFS advantage over chemotherapy alone in this setting. Lead investigator Daniel P. Petrylak, MD, Professor of Medicine and of Urol­ogy, Yale School of Medicine and Yale Cancer Center, New Haven, CT, presented the results at the 2017 European Society for Medical Oncology (ESMO) Congress. [ Read More ]